

Docket No.: 17849PCT

FORM PTO-1595 (Modified)
(Rev. 03-01)
OMB No. 0651-0027 (exp.5/31/2002)
P08A/REV04

RECORDATION FORM COVER SHEET

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

PATENTS ONLY

Tab settings → → → ▼ ▼ ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies): Pharmacia & Upjohn Company LLC</p> <p>Additional names(s) of conveying party(ies) <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and address of receiving party(ies):</p> <p>Name: <u>Nerviano Medical Sciences S.r.l.</u></p> <p>Address: <u>Viale Pasteur, 10</u></p> <p>City: <u>Nerviano, Milan</u> State/Prov.: _____</p> <p>Country: <u>Italy</u> ZIP: <u>20014</u></p> <p>Additional name(s) & address(es) <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>3. Nature of conveyance:</p> <p><input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger</p> <p><input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name</p> <p><input type="checkbox"/> Other _____</p> <p>Execution Date: <u>March 30, 2006</u></p>	

4. Application number(s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is: _____


<p>Patent Application No. <u>10/381,272</u></p> <p>Filing date <u>June 24, 2003</u></p> <p>Additional numbers <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>B. Patent No.(s)</p>
---	-------------------------

<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>Name: <u>Peter I. Bernstein</u></p> <p>Registration No. <u>43,497</u></p> <p>Address: <u>Scully, Scott, Murphy & Presser, P.C.</u></p> <p><u>400 Garden City Plaza, Suite 300</u></p> <p>City: <u>Garden City</u> State/Prov.: <u>New York</u></p> <p>Country: <u>USA</u> ZIP: <u>11530</u></p>	<p>6. Total number of applications and patents involved: 1</p> <p>7. Total fee (37 CFR 3.41):.....\$ <u>40.00</u></p> <p><input type="checkbox"/> Enclosed - Any excess or insufficiency should be credited or debited to deposit account</p> <p><input checked="" type="checkbox"/> Authorized to be charged to deposit account</p> <p>8. Deposit account number: <u>19-1013/SSMP</u></p> <p>(Attach duplicate copy of this page if paying by deposit account)</p>
---	--

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Peter I. Bernstein  December 7, 2006

Name of Person Signing Signature **7** Date

Total number of pages including cover sheet, attachments, and document: **7**

Mail documents to be recorded with required cover sheet information to:
Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
P.O. Box 1450, Alexandria, VA 22313-1450

PATENT

700300845

REEL: 018614 FRAME: 0420

ASSIGNMENT

WHEREAS, PHARMACIA & UPJOHN COMPANY LLC, is a registered company in Delaware, having a place of business at 301 Henrietta Street, Kalamazoo, Michigan 49001, (hereinafter, "ASSIGNOR");

WHEREAS, the ASSIGNOR owns certain rights in and to certain patents, utility models and patent applications (whether provisional or otherwise), for the United States of America and other countries foreign thereto;

WHEREAS, NERVIANO MEDICAL SCIENCES S.r.l., a registered company of Italy, having a place of business at Viale Pasteur, 10, Nerviano (MI), Italy 20014 (hereinafter, "ASSIGNEE");

Now, therefore, for good and valuable consideration, receipt of which is acknowledged, the ASSIGNOR has agreed to assign and transfer and does hereby assign and transfer unto ASSIGNEE, its successors and assigns, all of the right, title and interest which ASSIGNOR owns in and to the patents, utility models, and patent applications (whether provisional or otherwise), listed in the Patent Schedule (attached hereto and made a part hereof) and in and to any division, continuation or continuation-in-part, of said applications, and in and to any and all Letters Patent and reissues and extensions thereof, of the United States of America and all countries foreign thereto (including the right to apply for Letters Patent in foreign countries in its own name and to claim any priority rights for such foreign applications to which such applications are entitled under international conventions, treaties or otherwise), which have been or may be granted on any of the foregoing to be held and enjoyed as fully and exclusively as they would have been by ASSIGNOR had this assignment and transfer not been made;

The ASSIGNOR does further agree to execute and deliver without further consideration any further applications, assignment and documents, and to perform such other

acts as may be deemed necessary by said ASSIGNEE, its successors, assigns, and nominees, fully to secure its interest as aforesaid and to obtain or maintain Letters Patent in any and all countries;

And the undersigned do hereby authorize and request the U.S. Commissioner of Patents and Trademarks and the patent offices of all other countries of the world to issue any and all Letters Patents which may be granted upon any of the said applications, to the said ASSIGNEE, as the assignee of the entire interest herein.

In witness whereof, the undersigned have hereunto executed this document on the day and year set forth below.

ASSIGNOR

ASSIGNEE

PHARMACIA & UPJOHN COMPANY LLC

NERVIANO MEDICAL SCIENCES S.r.l.

by: Grover F. Fuller, Jr.
Name: Grover F. Fuller, Jr.
Title: Assistant Secretary

by: Dr. Francesco Colotta
Name: Dr. Francesco Colotta
Title: VP, Oncology

Date: 15 March 2006

Date: 30 MARCH 2006

Witness: [Signature]

Witness: [Signature]

<u>PATENT SCHEDULE</u>				
<u>TITLE</u>	<u>COUNTRY</u>	<u>APPLN.NO/ PATENT NO.</u>	<u>NMS REF.</u>	<u>PFIZER REF.</u>
Antitumor Therapy Comprising Distamycin Derivatives	Argentina	P010104621	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Armenia	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Australia	2002 221622	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Azerbaijan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Belarus	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Brazil	PI 0114389-1	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Canada	2,424,116	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Chile	2001-2373	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	China	01816755.1	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Colombia	03-035193	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Czech Republic	2003-909	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Estonia	P2003 00129	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Eurasia	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	EPO	01986259.8	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Hong Kong	04103423.7	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Hungary	P0301247	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	India	637/CHENP/03	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Indonesia	W00200300848	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Israel	154755	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Japan	2002-532214	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Kazakstan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Republic of Korea	2003-7004710	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Kyrgyz Republic	006295	PHA-00299	PC26786

Antitumor Therapy Comprising Distamycin Derivatives	Malaysia	PI20014542	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Mexico	2003-002824	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Moldova	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Norway	20031410	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Pakistan	137884	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Pakistan	925/2001	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Philippines	1-2003-500110	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Poland	P-363926	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Russian Federation	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Singapore	98094	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Slovakia	503-2003	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	South Africa	2003/3405	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Taiwan	90124050	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Tajikistan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Thailand	068610	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	Turkmenistan	006295	PHA-00299	PC26786
Antitumor Therapy Comprising Distamycin Derivatives	U.S.	6,576,612	PHA-00299	PC26786A
Antitumor Therapy Comprising Distamycin Derivatives	U.S.	10/381,272	PHA-00299	PC26786B
Antitumor Therapy Comprising Distamycin Derivatives	Venezuela	2001-002076	PHA-00299	PC26786

-END LIST-